Cargando…

LCOR Reverses Immune-Checkpoint Inhibitors Therapy Resistance Out of IFN Constraint in Triple-Negative Breast Cancer

Detalles Bibliográficos
Autores principales:	Zhou, Jialin, Feng, Chun, Huang, Kai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9326162/ https://www.ncbi.nlm.nih.gov/pubmed/35912168 http://dx.doi.org/10.3389/fonc.2022.911572

Ejemplares similares

Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
por: Thomas, Remy, et al.
Publicado: (2021)

Opioids and immune checkpoint inhibitors differentially regulate a common immune network in triple-negative breast cancer
por: Scarpa, Joseph R., et al.
Publicado: (2023)

Potential Predictive and Prognostic Value of Biomarkers Related to Immune Checkpoint Inhibitor Therapy of Triple-Negative Breast Cancer
por: Tan, Qiaorui, et al.
Publicado: (2022)

Immune Checkpoint Inhibition for Triple-Negative Breast Cancer: Current Landscape and Future Perspectives
por: Yi, Huimei, et al.
Publicado: (2021)

Lymphocyte-activating gene 3 expression in tumor cells predicts immune checkpoint inhibitor response in triple negative breast cancer
por: Kim, Ji-Yeon, et al.
Publicado: (2023)

Complex regulation of LCoR signaling in breast cancer cells
por: Jalaguier, S, et al.
Publicado: (2017)

RIP140 and LCoR expression in gastrointestinal cancers
por: Triki, Mouna, et al.
Publicado: (2017)

Immune Checkpoint Inhibitors Combined With Chemotherapy Compared With Chemotherapy Alone for Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis
por: Ji, Qiao, et al.
Publicado: (2021)

Case Report: Significant Response to the Combination of Lenvatinib and Immune Checkpoint Inhibitor in a Patient With Heavily Pretreated Metastatic Triple Negative Breast Cancer
por: Lee, Jin Sun, et al.
Publicado: (2021)

Regulation of LCoR and RIP140 expression in cervical intraepithelial neoplasia and correlation with CIN progression and dedifferentiation
por: Vogelsang, Tilman L. R., et al.
Publicado: (2020)

Efficacy and Safety of Adding Immune Checkpoint Inhibitors to Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials
por: Li, Yunhai, et al.
Publicado: (2021)

Normal and cancer mammary stem cells evade interferon-induced constraint through the miR-199a-LCOR Axis
por: Celià-Terrassa, Toni, et al.
Publicado: (2017)

Chidamide Reverses Fluzoparib Resistance in Triple-Negative Breast Cancer Cells
por: Li, Xinyang, et al.
Publicado: (2022)

The Degree of Programmed Death-Ligand 1 (PD-L1) Positivity as a Determinant of Outcomes in Metastatic Triple-Negative Breast Cancer Treated With First-Line Immune Checkpoint Inhibitors
por: Di Spazio, Lorenzo, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors in Triple Negative Breast Cancer: The Search for the Optimal Biomarker
por: Qureshi, Sadaf, et al.
Publicado: (2022)

Retinoic Acid Induces an IFN-Driven Inflammatory Tumour Microenvironment, Sensitizing to Immune Checkpoint Therapy
por: Tilsed, Caitlin M., et al.
Publicado: (2022)

Biomarkers for Immune Checkpoint Inhibitors in Melanoma
por: Kitano, Shigehisa, et al.
Publicado: (2018)

Immune Checkpoint Inhibitors in the Treatment of HCC
por: Donisi, Clelia, et al.
Publicado: (2021)

Clonogenicity-based radioresistance determines the expression of immune suppressive immune checkpoint molecules after hypofractionated irradiation of MDA-MB-231 triple-negative breast cancer cells
por: Gehre, Simon, et al.
Publicado: (2023)

New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer
por: Han, Ye, et al.
Publicado: (2020)

Nanomaterial Technology and Triple Negative Breast Cancer
por: Hou, Kai, et al.
Publicado: (2022)

Investigation of RIP140 and LCoR as independent markers for poor prognosis in cervical cancer
por: Vattai, Aurelia, et al.
Publicado: (2017)

Cyclin-Dependent Kinase Inhibitors Function as Potential Immune Regulators via Inducing Pyroptosis in Triple Negative Breast Cancer
por: Xu, Tao, et al.
Publicado: (2022)

Immune Checkpoint Inhibitor-induced Fanconi Syndrome
por: Farid, Saira, et al.
Publicado: (2020)

Checkpoint inhibitor therapy for metastatic triple-negative breast cancer
por: Heeke, Arielle L., et al.
Publicado: (2021)

Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors
por: Abdou, Yara, et al.
Publicado: (2022)

Neurological Manifestations Related to Immune Checkpoint Inhibitors: Reverse Translational Research by Using the European Real-World Safety Data
por: Ruggiero, Rosanna, et al.
Publicado: (2022)

Immune Lymphocyte Infiltrate and its Prognostic Value in Triple-Negative Breast Cancer
por: Huertas-Caro, Carlos Alexander, et al.
Publicado: (2022)

Editorial: Immune checkpoint inhibitors in renal cell carcinoma
por: Tykodi, Scott S., et al.
Publicado: (2023)

Radiotherapy plus immune checkpoint inhibitor in prostate cancer
por: Li, Tianjie, et al.
Publicado: (2023)

Importance of RIP140 and LCoR Sub-Cellular Localization for Their Association With Breast Cancer Aggressiveness and Patient Survival()
por: Sixou, Sophie, et al.
Publicado: (2018)

Updates in combined approaches of radiotherapy and immune checkpoint inhibitors for the treatment of breast cancer
por: Jungles, Kassidy M., et al.
Publicado: (2022)

Hyperprogression After Immune-Checkpoint Inhibitor Treatment: Characteristics and Hypotheses
por: Zang, Hongjing, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges
por: Liu, Hao-Tian, et al.
Publicado: (2021)

Current Status of Immune Checkpoint Inhibitor Immunotherapy for Lung Cancer
por: Xiong, Wei, et al.
Publicado: (2021)

Editorial: Biomarkers of Immune-Checkpoint-Inhibitor Immunotherapies in Hepatocellular Carcinomas
por: Guo, Zhanjun, et al.
Publicado: (2022)

Concomitant Medication Effects on Immune Checkpoint Inhibitor Efficacy and Toxicity
por: Sieber, Brendan, et al.
Publicado: (2022)

Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors
por: Irabor, Omoruyi Credit, et al.
Publicado: (2022)

Immune checkpoint inhibitors in advanced and recurrent/metastatic cervical cancer
por: Han, Xiling, et al.
Publicado: (2022)

Immune checkpoint inhibitors for unresectable or metastatic pleomorphic dermal sarcomas
por: Helbig, Doris, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_icic7dpn9rgq2o91j4lpv8v268